MannKind

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. 

CEO
Michael E. Castagna
CEOMichael E. Castagna
Employees
407
Employees407
Headquarters
Danbury, Connecticut
HeadquartersDanbury, Connecticut
Founded
1991
Founded1991
Employees
407
Employees407

MNKD Key Statistics

Market cap
1.75B
Market cap1.75B
Price-Earnings ratio
59.28
Price-Earnings ratio59.28
Dividend yield
Dividend yield
Average volume
2.54M
Average volume2.54M
High today
$5.81
High today$5.81
Low today
$5.58
Low today$5.58
Open price
$5.60
Open price$5.60
Volume
2.36M
Volume2.36M
52 Week high
$7.07
52 Week high$7.07
52 Week low
$3.38
52 Week low$3.38

Stock Snapshot

MannKind(MNKD) stock is priced at $5.71, giving the company a market capitalization of 1.75B. It carries a P/E multiple of 59.28.

During the trading session on 2025-12-04, MannKind(MNKD) shares reached a daily high of $5.81 and a low of $5.58. At a current price of $5.71, the stock is +2.3% higher than the low and still -1.7% under the high.

Trading volume for MannKind(MNKD) stock has reached 2.36M, versus its average volume of 2.54M.

The stock's 52-week range extends from a low of $3.38 to a high of $7.07.

The stock's 52-week range extends from a low of $3.38 to a high of $7.07.

MNKD News

Simply Wall St 6d
MannKind Is Up 6.4% After Wave of Analyst Upgrades Despite MNKD-101 Discontinuation – Has The Bull Case Changed?

Earlier this month, Truist Financial began covering MannKind and issued a positive analyst rating, following similar Buy ratings from Wells Fargo and ongoing su...

MannKind Is Up 6.4% After Wave of Analyst Upgrades Despite MNKD-101 Discontinuation – Has The Bull Case Changed?

Analyst ratings

100%

of 10 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own MNKD. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.